DND - Now I'm compelled to answer what you asked me not to. 

I'm just concerned that some might turt away ( or turn their backs on the company altogether) because of the unlikelihood of such a discovery.

In my pre and post investment dd I spoke to many people in the investment industry, pharma industry, scientists and MDs whether GPs or specialists and came to one common denominator. Without fail it was current or former pharma sales reps that turned up their nose or turned their back on the idea of a single drug that could have many targets and be successful at it. I had at least 8 experiences like that from this particular group of people. Thinking back a little each of those people had more than 20 experience in pharma sales. In the most recent presentation DM referred to how drugs were developed in the past, targeting one or a group of proteins and going forward with that approach. That comment was followed shortly by our drug touches on over 200 markers (or something to that effect). We are a first in class drug that that particular group of people may not have had any exposure to so in their experience their comments were valid. The scientists and specialists comments held the most validity to me. Thank you BDAZ you are in this group. The comments from nephrologists and neurologists were by far the most encouraging. A couple even went as far as saying "you won't be able to carry your billions home if it (apabetalone) works the way you say it should."

So here I am 12 or so years later hoping it works the way they say it should. It won't be long now. We either have it or we don't.

tada